Peregrine Pharmaceuticals CEO Nicholas Green receives $2.8M in 2021
Peregrine Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: August 27, 2021
Peregrine Pharmaceuticals reported fiscal year 2021 executive compensation information on August 27, 2021.
In 2021, four executives at Peregrine Pharmaceuticals received on average a compensation package of $1.5M, a 83% increase compared to previous year.
Nicholas S. Green, Chief Executive Officer, received $2.8M in total. 38% of Green's compensation, or $1.1M, was in stock awards. Green also received $138K in bonus, $723K in non-equity incentive plan, $347K in option awards, $421K in salary, as well as $127K in other compensation.
For fiscal year 2021, the median employee pay was $104,222 at Peregrine Pharmaceuticals. Therefore, the ratio of Nicholas S. Green's pay to the median employee pay was 27 to one.
Daniel R. Hart, Chief Financial Officer, received a compensation package of $1.3M, which increased by 60% compared to previous year. 31% of the compensation package, or $424K, was in salary.
Mark R. Ziebell, General Counsel, earned $1.1M in 2021, a 3% decrease compared to previous year.
Richard B. Hancock, Chief Executive Officer, received $926K in 2021, which increases by 20% compared to 2020.
Peregrine Pharmaceuticals' fiscal year ends on April 30.